Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation in Adults

Clinical Medicine Insights: Gastroenterology- New Zealand

doi 10.4137/cgast.s10550

Full Text

Abstract

Available in

Date

Authors

Publisher

SAGE Publications

Related search

Prescribing Patterns for Outpatient Treatment of Constipation, Irritable Bowel Syndrome-Related Constipation, and Opioid-Induced Constipation: A Retrospective Cross-Sectional Study

Journal of managed care & specialty pharmacy
Health PolicyPharmacyPharmaceutical Science
2015English

Clinical and Experimental Study on Probiotics in the Treatment of Constipation Type Irritable Bowel Syndrome

Biomarkers and Applications
2019English

Pgi8 - Systematic Literature Review and Indirect Treatment Comparison of Linaclotide Versus Other Oral Constipation Treatments in Patients With Chronic Constipation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

American Journal of Gastroenterology
HepatologyGastroenterology
2012English

PTU-152 Significant Improvements in Abdominal Pain and Bowel Symptoms in a Phase 3 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): A European Perspective

Gut
Gastroenterology
2012English

Clinical Response to Linaclotide at Week 4 Predicts Sustained Response in Irritable Bowel Syndrome With Constipation and Improvements in Digestive and Extra-Digestive Symptoms

Therapeutic Advances in Gastroenterology
Gastroenterology
2019English

Irritable Bowel Syndrome Subtype Screening Characteristics: Constipation Subtype Patient Profiles Explored

Gastroenterology Insights
HepatologyGastroenterology
2012French

Pgi46 - Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (Dibss-C)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PWE-026 Effects of 26 Weeks of Linaclotide Treatment on Adequate Relief and IBS Severity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): Abstract PWE-026 Table

Gut
Gastroenterology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy